RxDoctor Payments Data

Mario Leone, MD

Nephrology · Youngstown, OHNPI 1578060927

Payments from drug & device makers

$3,225in general payments, 2019–2025

Across 131 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$545
  • Otsuka America Pharmaceutical, Inc.$484
  • AstraZeneca$453
  • Calliditas Therapeutics US Inc.$422
  • Aurinia Pharma U.S., Inc.$322
  • Amgen$241
  • plus $757 from 11 others

What the payments were for

  • Food & beverage$3,20699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,225 in reported general payments places this provider in the 65th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$153,354
Medicare patients
513
Services billed
1,832

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate13$12,520
Sevelamer Carbonate20$1,701
Olmesartan Medoxomil12$1,391
Amlodipine Besylate95$385
Calcitriol32$340
Lisinopril85$312
Furosemide86$293
Losartan Potassium70$225
Hydralazine Hcl11$194
Allopurinol17$148
Potassium Chloride12$141
Chlorthalidone12$134
Hydrochlorothiazide37$132
Valsartan12$95
Spironolactone24$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$453$12,52013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 450 nephrology providers in Ohio.

Other nephrology in Youngstown

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →